European policymakers, researchers, healthcare leaders and patient advocates will gather in Stockholm from 14 to 16 October for Momentum 2026. The conference will examine how Europe can shorten the path from cancer research to patient benefit through stronger collaboration and faster adoption of scientific advances. Speakers include Greg Simon, Joanna Drake, Cary Adams and Elisabete Weiderpass. Journalists are welcome to apply for accreditation.

A previously unknown protein, hidden in RNA thought not to encode proteins, helps cells divide correctly. The RNA molecule that encodes the protein also has a function of its own in cell division. The findings from the University of Gothenburg could provide new insights into what goes wrong in conditions such as cancer.

BUFFALO, NY — September 25, 2026 — A new research perspective was published in Volume 13 of Oncoscience on September 17, 2026, titled “Emerging pharmacological agents for glioblastoma multiforme: An update on active clinical trials (2025–2026).”

Conventional CAR-T therapy requires collecting T cells, genetically modifying them in the laboratory, and reinfusing the engineered cells—a process that takes weeks and costs lots of money. A new review systematically examines in vivo CAR-T approaches that perform this entire reprogramming process inside the patient's body using targeted delivery systems. The article analyzes delivery platforms, evaluates clinical translation progress, and discusses strategies for overcoming key challenges, including off-target effects, immunogenicity, and T cell exhaustion.

Researchers have developed a laser-assisted method that rapidly detects tiny amounts of CEACAM-5, a colorectal cancer biomarker, in blood. The technique enhances antibody–antigen interactions and achieves detection even at low concentrations within minutes. The researchers also identified nanoscale CEACAM-5 aggregates that may enhance the method’s sensitivity.

Researchers at the University of Maryland, Baltimore County (UMBC) have identified the enzyme USP15 as a promising molecular target for ovarian cancer therapy. Their study shows that ovarian cancer cells rely more heavily on USP15 than normal cells. Lowering USP15 levels slows tumor growth, disrupts chromosome separation during cell division, reduces the cancer’s ability to spread, and makes cells more sensitive to standard chemotherapy drugs. The findings, published in Molecular Therapy Oncology, open the door to more selective treatments that could reduce harm to healthy cells.